Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06579105 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 406
- Enrollment target
NCT06579105 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 406 participants.
The verdict
NCT06579105, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 406 participants
- Enrollment target
Study Summary
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Interventions
- DRUG Semaglutide
- DRUG AZD5004
- DRUG Placebo (placebo matching AZD5004 film-coated tablet)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2025-12-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06579105
The ClinicalTrials.gov registry entry for NCT06579105 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Semaglutide is the first listed.
NCT06579105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06579105 about?
NCT06579105 is a clinical study titled "Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.". This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
What is the current status of trial NCT06579105?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 406 participants. The study started on 2024-10-08. Estimated completion is 2025-12-19.
What interventions are being tested in trial NCT06579105?
The interventions under investigation include: Semaglutide (DRUG), AZD5004 (DRUG), Placebo (placebo matching AZD5004 film-coated tablet) (DRUG).
Who is sponsoring clinical trial NCT06579105?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.